Please use this identifier to cite or link to this item:
http://hdl.handle.net/10397/106105
DC Field | Value | Language |
---|---|---|
dc.contributor | Department of Land Surveying and Geo-Informatics | en_US |
dc.creator | Wai, AKC | en_US |
dc.creator | Lee, TTL | en_US |
dc.creator | Chan, SCL | en_US |
dc.creator | Chan, CY | en_US |
dc.creator | Yip, ETF | en_US |
dc.creator | Luk, LYF | en_US |
dc.creator | Ho, JWK | en_US |
dc.creator | So, KWL | en_US |
dc.creator | Tsui, OWK | en_US |
dc.creator | Lam, ML | en_US |
dc.creator | Lee, SY | en_US |
dc.creator | Yamamoto, T | en_US |
dc.creator | Tong, CK | en_US |
dc.creator | Wong, MS | en_US |
dc.creator | Wong, ELY | en_US |
dc.creator | Rainer, TH | en_US |
dc.date.accessioned | 2024-05-03T00:45:12Z | - |
dc.date.available | 2024-05-03T00:45:12Z | - |
dc.identifier.uri | http://hdl.handle.net/10397/106105 | - |
dc.language.iso | en | en_US |
dc.publisher | Nature Publishing Group | en_US |
dc.rights | Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. | en_US |
dc.rights | © The Author(s) 2023 | en_US |
dc.rights | The following publication Wai, A.Kc., Lee, T.Tl., Chan, S.Cl. et al. Association of Molnupiravir and Nirmatrelvir-Ritonavir with reduced mortality and sepsis in hospitalized omicron patients: a territory-wide study. Sci Rep 13, 7832 (2023) is available at https://dx.doi.org/10.1038/s41598-023-35068-w. | en_US |
dc.title | Association of Molnupiravir and Nirmatrelvir-Ritonavir with reduced mortality and sepsis in hospitalized omicron patients : a territory-wide study | en_US |
dc.type | Journal/Magazine Article | en_US |
dc.identifier.volume | 13 | en_US |
dc.identifier.doi | 10.1038/s41598-023-35068-w | en_US |
dcterms.abstract | This study evaluates the association between antivirals (Molnupiravir and Nirmatrelvir-Ritonavir) and all-cause and respiratory mortality and organ dysfunction among high-risk COVID-19 patients during an Omicron outbreak. Two cohorts, Nirmatrelvir-Ritonavir versus control and Molnupiravir versus control, were constructed with inverse probability treatment weighting to balance baseline characteristics. Cox proportional hazards models evaluated the association of their use with all-cause mortality, respiratory mortality, and all-cause sepsis (a composite of circulatory shock, respiratory failure, acute liver injury, coagulopathy, and acute liver impairment). Patients recruited were hospitalized and diagnosed with the COVID-19 Omicron variant between February 22, 2022 and April 15, 2022, and followed up until May 15, 2022. The study included 17,704 patients. There were 4.67 and 22.7 total mortalities per 1000 person-days in the Nirmatrelvir-Ritonavir and control groups respectively before adjustment (weighted incidence rate ratio, - 18.1 [95% CI - 23.0 to - 13.2]; hazard ratio, 0.18 [95% CI, 0.11-0.29]). There were 6.64 and 25.9 total mortalities per 1000 person-days in the Molnupiravir and control groups respectively before adjustment (weighted incidence rate ratio per 1000 person-days, - 19.3 [95% CI - 22.6 to - 15.9]; hazard ratio, 0.23 [95% CI 0.18-0.30]). In all-cause sepsis, there were 13.7 and 35.4 organ dysfunction events per 1000 person-days in the Nirmatrelvir-Ritonavir and control groups respectively before adjustment (weighted incidence rate ratio per 1000 person-days, - 21.7 [95% CI - 26.3 to - 17.1]; hazard ratio, 0.44 [95% CI 0.38-0.52]). There were 23.7 and 40.8 organ dysfunction events in the Molnupiravir and control groups respectively before adjustment (weighted incidence ratio per 1000 person-days, - 17.1 [95% CI, - 20.6 to - 13.6]; hazard ratio, 0.63 [95% CI 0.58-0.69]). Among COVID-19 hospitalized patients, use of either Nirmatrelvir-Ritonavir or Molnupiravir compared with no antiviral use was associated with a significantly lower incidence of 28-days all-cause and respiratory mortality and sepsis. | en_US |
dcterms.accessRights | open access | en_US |
dcterms.bibliographicCitation | Scientific reports, 2023, v. 13, 7832 | en_US |
dcterms.isPartOf | Scientific reports | en_US |
dcterms.issued | 2023 | - |
dc.identifier.isi | WOS:000989082600023 | - |
dc.identifier.eissn | 2045-2322 | en_US |
dc.identifier.artn | 7832 | en_US |
dc.description.validate | 202405 bcrc | en_US |
dc.description.oa | Version of Record | en_US |
dc.identifier.FolderNumber | OA_Scopus/WOS | - |
dc.description.fundingSource | Others | en_US |
dc.description.fundingText | Center for Health Systems and Policy Research | en_US |
dc.description.fundingText | Tung's Foundation | en_US |
dc.description.fundingText | AIR@InnoHK of the Innovation and Technology Commission | en_US |
dc.description.pubStatus | Published | en_US |
dc.description.oaCategory | CC | en_US |
Appears in Collections: | Journal/Magazine Article |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
s41598-023-35068-w.pdf | 2.1 MB | Adobe PDF | View/Open |
Page views
14
Citations as of Jun 30, 2024
Downloads
4
Citations as of Jun 30, 2024
SCOPUSTM
Citations
1
Citations as of Jun 21, 2024
WEB OF SCIENCETM
Citations
1
Citations as of Jul 4, 2024
![](/image/google_scholar.jpg)
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.